Results of OncoGenex phase I/II Custirsen trial published

Friday, January 6, 2012 09:32 AM

OncoGenex Pharmaceuticals has reported results of a phase I/II study to determine the effectiveness of its investigational compound custirsen in conjunction with a gemcitabine/platinum-based regimen in patients with advanced non-small cell lung cancer (NSCLC).

Results published in the January 2012 issue of the Journal of Thoracic Oncology showed the additional treatment of custirsen, designed to block production of tumor cell survival protein clusterin, improved survival rates by three to seven months longer than patients who adhered to only a gemcitabine/platinum-based regimen. The combination treatment produced a median overall survival of 14.1 months, and progression-free survival of 4.3 months. Moreover, the patients who achieved a threshold minimum of serum clusterin (</= 45mcg/mL) had a median survival of 27.1 months.

Additionally, the study determined the toxicity of the combination treatment was not appreciably different from that reported for a gemcitabine/platinum-based regimen on its own.

"The identification and targeting of new therapeutic pathways, such as clusterin inhibition, are required in order to improve outcomes for cancer patients," said Dr. Janessa Laskin, principal investigator on the study and a medical oncologist at the British Columbia Cancer Centre.

The single-arm trial, conducted at 15 sites in North America, consisted of 81 patients with untreated, advanced NSCLC. OncoGenex has entered a collaboration and license agreement for custirsen with Teva Pharmaceutical Industries. The companies are planning a randomized, phase III study of custirsen as a first-line treatment of advanced, unresectable non-small cell lung cancer.

Share:          
CLINICAL TRIAL RESOURCES

Search:

NEWS ONLINE ARCHIVE

Browse by:

CWWeekly

December 15

Cancer Treatment Centers of America chooses WCG as its exclusive IRB, sheds five local hospital IRBs

Five southern research groups form public-private network to help save time, money for clients with early-stage biologics

Already a subscriber?
Log in to your digital subscription.

Subscribe to CWWeekly.

The CenterWatch Monthly

December

Growing adoption of feasibility review committees
Early reports cite fewer amendments, improved cycle time

AMCs vying to better compete for industry trials
Working to conquer study start-up delays, IRB review process

Already a subscriber?
Log in to your digital subscription.

Purchase the October issue.

Subscribe to
The CenterWatch Monthly.

The CenterWatch Monthly

November

Private equity driving dynamic CRO growth
Enables CROs to pursue long-term strategies, while giving the space credibility

Baby boomers poised to reshape clinical trials industry
Millions of tech-savvy consumers already track their health, expect new treatments as they age

Already a subscriber?
Log in to your digital subscription.

Purchase the September issue.

Subscribe to
The CenterWatch Monthly.

JobWatch centerwatch.com/jobwatch

Featured Jobs